The stock of ATAI Life Sciences N.V. (ATAI) has gone up by 1.37% for the week, with a 10.45% rise in the past month and a -25.25% drop in the past quarter. The volatility ratio for the week is 8.01%, and the volatility levels for the past 30 days are 7.43% for ATAI. The simple moving average for the last 20 days is 7.25% for ATAI stock, with a simple moving average of -8.17% for the last 200 days.
Is It Worth Investing in ATAI Life Sciences N.V. (NASDAQ: ATAI) Right Now?
ATAI has 36-month beta value of 0.84. Analysts have mixed views on the stock, with 0 analysts rating it as a “buy,” 0 as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for ATAI is 116.70M, and currently, short sellers hold a 7.13% ratio of that float. The average trading volume of ATAI on July 19, 2024 was 918.71K shares.
ATAI) stock’s latest price update
ATAI Life Sciences N.V. (NASDAQ: ATAI)’s stock price has plunge by -7.50relation to previous closing price of 1.60. Nevertheless, the company has seen a 1.37% surge in its stock price over the last five trading sessions. zacks.com reported 2024-07-11 that atai Life Sciences (ATAI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company’s earnings prospects. This might drive the stock higher in the near term.
Analysts’ Opinion of ATAI
Many brokerage firms have already submitted their reports for ATAI stocks, with Maxim Group repeating the rating for ATAI by listing it as a “Buy.” The predicted price for ATAI in the upcoming period, according to Maxim Group is $6 based on the research report published on April 03, 2024 of the current year 2024.
Loop Capital, on the other hand, stated in their research note that they expect to see ATAI reach a price target of $18. The rating they have provided for ATAI stocks is “Buy” according to the report published on November 01st, 2022.
Maxim Group gave a rating of “Buy” to ATAI, setting the target price at $25 in the report published on November 30th of the previous year.
ATAI Trading at -4.60% from the 50-Day Moving Average
After a stumble in the market that brought ATAI to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -48.07% of loss for the given period.
Volatility was left at 7.43%, however, over the last 30 days, the volatility rate increased by 8.01%, as shares surge +16.54% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -30.19% lower at present.
During the last 5 trading sessions, ATAI rose by +1.37%, which changed the moving average for the period of 200-days by +14.73% in comparison to the 20-day moving average, which settled at $1.3905. In addition, ATAI Life Sciences N.V. saw 4.96% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ATAI starting from Brand Florian, who sale 151,303 shares at the price of $1.92 back on May 16 ’24. After this action, Brand Florian now owns 328,697 shares of ATAI Life Sciences N.V., valued at $290,502 using the latest closing price.
Rao Srinivas, the of ATAI Life Sciences N.V., sale 61,640 shares at $1.85 during a trade that took place back on Apr 02 ’24, which means that Rao Srinivas is holding 113,360 shares at $114,034 based on the most recent closing price.
Stock Fundamentals for ATAI
Current profitability levels for the company are sitting at:
- -419.65 for the present operating margin
- -0.64 for the gross margin
The net margin for ATAI Life Sciences N.V. stands at -122.03. The total capital return value is set at -0.46. Equity return is now at value -14.72, with -12.30 for asset returns.
Based on ATAI Life Sciences N.V. (ATAI), the company’s capital structure generated 0.07 points at debt to capital in total, while cash flow to debt ratio is standing at -5.45. The debt to equity ratio resting at 0.07. The interest coverage ratio of the stock is -42.7.
Currently, EBITDA for the company is -125.15 million with net debt to EBITDA at 0.06. When we switch over and look at the enterprise to sales, we see a ratio of 867.67. The receivables turnover for the company is 0.11for trailing twelve months and the total asset turnover is 0.0. The liquidity ratio also appears to be rather interesting for investors as it stands at 7.83.
Conclusion
To put it simply, ATAI Life Sciences N.V. (ATAI) has had a mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
